Economic aspects of epilepsy;Aspectos economicos de la epilepsia

Revista de Neurologia

Volumn 30, Issue SUPPL. 1, 2000, Pages

  Argumosa, A ^a   Herranz, J L ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Cost analysis; Cost of illness; Epilepsy; Pharmaco economy

Indexed keywords

ANTICONVULSIVE AGENT;

CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC ASPECT; EMPLOYMENT; EPILEPSY; HEALTH CARE COST; HEALTH CARE UTILIZATION; ADULT; COST; ECONOMICS; HUMAN; REVIEW;

ADULT; COSTS AND COST ANALYSIS; EPILEPSY; HUMANS;

EID: 0033928561     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. Colombian League against Epilepsy. Colombian cost of drugs. Meeting of ILAE Commission on Economic Aspects of Epilepsy. Bielefeld, March 8-9, 1996.
2. Jacoby A. Impact of epilepsy on employment status: findings from a UK study of people with well-controlled epilepsy. Epilepsy Res 1995; 21: 125-32.
3. Jacoby A, Buck D, Baker G, McNamee P, Graham-Jones S, Chadwick D. Uptake and cost of care for epilepsy: findings from a U.K. regional study. Epilepsia 1998; 39: 776-86.
4. Cockerell OC, Johnson AL, Sander JW, Hart YM, Goodridge DM, Shorvon SD. Mortality from epilepsy: results from a prospective population-based study. Lancet 1994; 344: 918-21.
5. Murray MI, Halpern MT, Leppik IE. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996; 23: 139-48.
6. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with epilepsy: a European Study. Epilepsia 1997; 38: 353-62.
7. Gisbert R, Brosa M, Figueras M, Mindán E, Rovira J. El coste de la enfermedad en España: el coste de las enfermedades cardiovasculares. Madrid: Merck Sharp & Dohme de España, SA. 10-98-GEN-97-E-3124-B. 88 páginas.
8. Grupos terapéuticos y principios activos de mayor consumo en el Sistema Nacional de Salud durante 1997. Información terapéutica del Sistema Nacional de Salud 1998; 22: 123-5,
9. Murray CJL, Lopez AD, eds. Global comparative assessments in the health sector: disease burden, expenditures and intervention packages. Geneva: World Health Organization; 1994.
10. Begley CE, Annegers JF, Lairson DR, Reynolds TF, Hauser WA. The lifetime cost of epilepsy in the United States: a model based on incidence and prognosis. In Beran RG, Pachlatko C, eds. Cost of Epilepsy: Proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 17-26.
11. Banks GK, Regan KJ, Beran RG. The prevalence and direct cost of . epilepsy in Australia. In Beran RG, Pachlatko C, eds. Cost of Epilepsy: Proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 39-48.
12. Beran R, Banks GK. Indirect cost of epilepsy in Australia. In Beran RG, Pachlatko C, eds. Cost of Epilepsy: Proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 49-54.
13. Chandra B. Economic aspects of epilepsy in Indonesia. In Beran RG, Pachlatko C, eds. Cost of Epilepsy: Proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 75-82.
14. Silfvenius H, Lindholm L, Säisä J, Olivecrona M, Uverbrant P, Chirstianson SA. Cost of savings from paediatrics epilepsy surgery: a Swedish study. In Beran RG, Pachlatko C, eds. Cost of Epilepsy: Proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 83-106.
15. Cockerell OC, Hart YM, Sander JW, Shorvon SD. The cost of epilepsy in the United Kingdom. In Beran RG, Pachlatko C, eds. Cost of Epilepsy: Proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 27-38.
16. Gessner U, Sagmeister M, Horisberger B. The economic impact of epilepsy in Switzerland. In Beran RG, Pachlatko C, eds. Cost of Epilepsy: Proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 67-74.
17. Sacristán del Castillo JA, Badía X, Rovira J, eds. Farmacoeconomía: evaluación económica de medicamentos. Madrid: Editores Médicos; 1995.
18. Banks GK, Beran RG, Regan KJ. The prevalence and cost of epilepsy in Australia. Epilepsia 1993; 34 (Suppl 2): S146.
19. Begley CE, Annegers JF, Lairson DR, Reynolds TF, Hauser WA. Cost of Epilepsy in the United States: a model based on incidences and prognosis. Epilepsia 1994; 35: 1230-43.
20. Swingler RJ, Davidson DLW, Roberts RC, Moulding F. The cost of epilepsy in patients attending a specialist epilepsy service. Seizure 1994; 3: 115-20.
21. Cockerell OC, Hart YM, Sander JW, Shorvon SD. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population based studies. Epilepsy Res 1994; 18: 249-60.
22. Baker GA, Nashef L, Van Hout BA. Current issues in the management of epilepsy: the impact of frequent seizures on cost of illness, quality of life, and mortality. Epilepsia 1997; 38 (Suppl 1): S1-8.
23. Berto P, Tinuper P, Viaggi S. Cost of epilepsy patient in Italy: data from a multicenter observational study (Episcreen). Epilepsia 1998; 39 (Suppl 2): S118.
24. Beran R, Pachlatko C. Report of International League Against Epilepsy Commission on Economic Aspects of Epilepsy. Epilepsia 1996; 37: 506-8.
25. Johnson WG. The cost of epilepsy and cost-based evaluations of anti-convulsants. Pharmacoeconomics 1997; 12: 446-59.
26. Begley CE, Annegers JF, Lairson DR, Reynolds TF. Methodological issues in estimating the cost of epilepsy. Epilepsy Res 1999; 33: 39-55.
27. Beran RG, Banks GK. Australian experience with Submission of Heath economic appraisals of antiepileptic medication for Pharmaceutical benefits Listing. In Pachlatko CH, Beran RG, eds. Economic evaluation of epilepsy management. London: John Libbey; 1995. p. 59-65.
28. Brasfield KH. Pilot study of divalproex sodium versus valproic acid: drug acquisition costs versus all related costs. Current Ther Res 1998; 60: 138-44.
29. Marcheti A, Magar R, Fischer J. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebryx) versus intravenous phenytoin (Dilantin) in hospital emergency departments. Clin Ther 1996; 18: 953-66.
30. Heaney DC, Shorvon SD, Sander JW. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 1998; 39 (Suppl 3): S19-25.
31. Shakespeare A, Simeon G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure 1998; 7: 119-25.
32. Hughes D, Cockerell OC. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure 1996; 5: 89-95.
33. Markowitz MA, Mauskopf JA, Halpern MT. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology 1998; 51: 1026-33.
34. O'Neill BA, Trimble MR, Bloom DS. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options. Seizure 1995; 4: 37-44.
35. Hout BV, Gagnon D, Martens L, McNulty P. Cost-effectiveness of topiramate as add-on therapy in stable patients with refractory partial-onset epilepsy. Epilepsia 1999; 37 (Suppl 4): S79.
36. Keene D, Ventureyra EC. Epilepsy surgery for 5- to 18-year old patients with medical refractory epilepsy- is it cost efficient? Childs Nerv Syst 1999; 15: 52-5.
37. Hout BV, Gagnon D, Souêtre E, Ried S, Remy C, Baker G, et al. Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany and United Kingdom. Epilepsia 1997; 38: 1221-6.
38. Messori A, Trippoli S, Becagli P, Cincotta M, Labbate MG, Zaccara G. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol 1998; 53: 421-7.
39. Argumosa A, Herranz JL. El coste económico de la epilepsia infantil en España. Rev Neurol 2000; 30: 104-8.
40. Muller C, Fahs MC, Mulak G, Walther V, Blumenfield S, Fulop G. Pediatric AIDS at Mount Sinai Medical Center 1988-89: a study of costs and social severity. Soc Work Health Care 1996; 22: 1-20.
41. Orejas G, Malaga S, Santos F, Martínez I, Rodríguez LM, Rey C. Manejo del niño con insuficiencia renal crónica no terminal. Una aproximación al coste medio anual. An Esp Pediatr 1990; 33: 335-8.
42. Gray A, Fenn P, McGuire A. The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales. Diabet Med 1995; 12: 1068-76.
43. Lozano P, Sullivan SD, Smith DH, Weiss KB. The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey. J Allergy Clin Immunol 1999; 104: 957-63.
44. Kemp AS. Atopic eczema: its social and financial costs. J Paediatr Child Health 1999; 35: 229-31.